Major baseline characteristics of 113 HIV-infected patients at MCD diagnosis
| . | No. with complete data . | R− group (n = 65) . | R+ group (n = 48) . |
|---|---|---|---|
| Date of MCD diagnosis, n (%) | 113 | ||
| 1996-2000 | 27 (41.5) | 9 (19) | |
| 2001-2005 | 15 (23) | 16 (33) | |
| 2005-2011 | 23 (35) | 23 (48) | |
| Demographic characteristics | |||
| Sex, M:F | 113 | 56:9 | 36:12 |
| Median age, y (IQR) | 113 | 42 (36-48) | 43 (35-51) |
| Body mass index, n (%) | 96 | ||
| Underweight | 14 (28) | 4 (9) | |
| Normal | 32 (64) | 36 (78) | |
| Overweight | 4 (8) | 6 (13) | |
| HIV characteristics | |||
| Median HIV duration, y (IQR) | 113 | 3.0 (0.6-9.2) | 3.6 (0.6-9.2) |
| Prior AIDS, n (%) | 113 | 44 (68) | 27 (56) |
| Prior KS, n (%) | 113 | 40 (61.5) | 20 (42) |
| cART, n (%) | 113 | 34 (52) | 33 (69) |
| Median cART duration, mo (IQR) | 14.3 (1.7-23.9) | 31.3 (10.2-45.4) | |
| HIV-RNA ≤ 500 copies/mL, n (%) | 111 | 20 (31) | 26 (55) |
| CD4+ cell count | 112 | ||
| median, ×106/L, median (IQR) | 168 (73-264) | 213 (138-360) | |
| ≤ 200 × 106/L, n (%) | 39 (61) | 21 (44) | |
| nadir < 100 × 106/L, n (%) | 27 (47) | 15 (33) | |
| MCD characteristics, n (%) | |||
| ECOG > 2 | 110 | 29 (46) | 20 (42.5) |
| Hemophagocytosis | 109 | 24 (39) | 15 (32) |
| ICU stay | 105 | 15 (24) | 16 (37) |
| Hemoglobin ≤ 8 g/dL | 109 | 32 (52) | 20 (42.5) |
| Platelets < 50 × 109/L | 108 | 18 (29.5) | 13 (28) |
| LDH > normal | 103 | 26 (37) | 30 (68) |
| Serum albumin ≤ 25 g/L | 104 | 24 (41) | 19 (42) |
| Gammaglobulin ≥ 20 g/L | 103 | 37 (63) | 30 (68) |
| Prothrombin time ≤ 70% | 100 | 30 (53) | 22 (51) |
| . | No. with complete data . | R− group (n = 65) . | R+ group (n = 48) . |
|---|---|---|---|
| Date of MCD diagnosis, n (%) | 113 | ||
| 1996-2000 | 27 (41.5) | 9 (19) | |
| 2001-2005 | 15 (23) | 16 (33) | |
| 2005-2011 | 23 (35) | 23 (48) | |
| Demographic characteristics | |||
| Sex, M:F | 113 | 56:9 | 36:12 |
| Median age, y (IQR) | 113 | 42 (36-48) | 43 (35-51) |
| Body mass index, n (%) | 96 | ||
| Underweight | 14 (28) | 4 (9) | |
| Normal | 32 (64) | 36 (78) | |
| Overweight | 4 (8) | 6 (13) | |
| HIV characteristics | |||
| Median HIV duration, y (IQR) | 113 | 3.0 (0.6-9.2) | 3.6 (0.6-9.2) |
| Prior AIDS, n (%) | 113 | 44 (68) | 27 (56) |
| Prior KS, n (%) | 113 | 40 (61.5) | 20 (42) |
| cART, n (%) | 113 | 34 (52) | 33 (69) |
| Median cART duration, mo (IQR) | 14.3 (1.7-23.9) | 31.3 (10.2-45.4) | |
| HIV-RNA ≤ 500 copies/mL, n (%) | 111 | 20 (31) | 26 (55) |
| CD4+ cell count | 112 | ||
| median, ×106/L, median (IQR) | 168 (73-264) | 213 (138-360) | |
| ≤ 200 × 106/L, n (%) | 39 (61) | 21 (44) | |
| nadir < 100 × 106/L, n (%) | 27 (47) | 15 (33) | |
| MCD characteristics, n (%) | |||
| ECOG > 2 | 110 | 29 (46) | 20 (42.5) |
| Hemophagocytosis | 109 | 24 (39) | 15 (32) |
| ICU stay | 105 | 15 (24) | 16 (37) |
| Hemoglobin ≤ 8 g/dL | 109 | 32 (52) | 20 (42.5) |
| Platelets < 50 × 109/L | 108 | 18 (29.5) | 13 (28) |
| LDH > normal | 103 | 26 (37) | 30 (68) |
| Serum albumin ≤ 25 g/L | 104 | 24 (41) | 19 (42) |
| Gammaglobulin ≥ 20 g/L | 103 | 37 (63) | 30 (68) |
| Prothrombin time ≤ 70% | 100 | 30 (53) | 22 (51) |
ECOG indicates Eastern Collaborative Oncology Group performance status score; KS, Kaposi sarcoma; ICU, intensive care unit; and LDH, serum lactate dehydrogenase.